Sutro BioPharma

Major readouts on the horizon for small developers
Major readouts on the horizon for small developers
EP Vantage
Aldeyra Therapeutics
Autolus Therapeutics
Bavarian Nordic
BioXcel Therapeutics
Disc Medicine
Editas Medicine
Immunogen
Lantheus
Mersana Therapeutics
NGM Biopharmaceuticals
Omeros
Roche
Sutro BioPharma
uniQure
Valneva
Viking Therapeutics
Flag link:
Sutro shells out latest update on ovarian cancer treatment, plans for pivotal trial
Sutro shells out latest update on ovarian cancer treatment, plans for pivotal trial
Endpoints
Sutro BioPharma
clinical trials
antibody-drug conjugate
ovarian cancer
luveltamab tazevibulin
Flag link:
Astellas pumps $90m into Sutro immuno-oncology alliance
Astellas pumps $90m into Sutro immuno-oncology alliance
Pharmaforum
Astellas
Sutro BioPharma
antibody-drug conjugate
cancer
immuno-oncology
Flag link:
Biopharma developments over the Christmas period
Biopharma developments over the Christmas period
EP Vantage
Alnylam Pharmaceuticals
Bio-Thera Solutions
BioArctic
Biogen
BridgeBio Pharma
Daiichi Sankyo
Eisai
JNJ
Madrigal Pharmaceuticals
Merck
Sutro BioPharma
Tasly Pharmaceutical Group
Flag link:
Sutro bucks the folate trend
Sutro bucks the folate trend
EP Vantage
Sutro BioPharma
STRO-002
Flag link:
The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
Yahoo/Benzinga
Adamis Pharmaceuticals
Redhill Biopharma
Amag Pharmaceuticals
Arqule
Agile Therapeutics
Agios Pharmaceuticals
Deciphera
Mirati Therapeutics
Sutro BioPharma
Merck
Pfizer
Amgen
EXACT Sciences
Bristol-Myers Squibb
Celgene
Oyster Point Pharma
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
Flag link:
Nasdaq triple IPO play brings in $345M as the big biotech party rocks on
Nasdaq triple IPO play brings in $345M as the big biotech party rocks on
Endpoints
NASDAQ
IPOs
Entasis
Urovant Sciences
Arvinas
Sutro BioPharma
Flag link:
Immuno-Oncology Players Gritstone And Sutro Join The Biotech IPO Frenzy
Immuno-Oncology Players Gritstone And Sutro Join The Biotech IPO Frenzy
Forbes
biotech
IPOs
immuno-oncology
Gritstone Oncology
Sutro BioPharma
Flag link:
Sutro Biopharma, Arvinas Are Latest to Tee Up Biotech IPOs
Sutro Biopharma, Arvinas Are Latest to Tee Up Biotech IPOs
Xconomy
biotech
IPOs
Sutro BioPharma
Arvinas
cancer
Flag link:
Days after Merck deal, Sutro rolls out $85M E round to fund internal cancer pipeline
Days after Merck deal, Sutro rolls out $85M E round to fund internal cancer pipeline
Endpoints
Sutro BioPharma
cancer
Merck
Flag link: